» Articles » PMID: 38817914

Ten Tips on How to Assess Bone Health in Patients with Chronic Kidney Disease

Overview
Journal Clin Kidney J
Specialty Nephrology
Date 2024 May 31
PMID 38817914
Authors
Affiliations
Soon will be listed here.
Abstract

Patients with chronic kidney disease (CKD) experience a several-fold increased risk of fracture. Despite the high incidence and the associated excess morbidity and premature mortality, bone fragility in CKD, or CKD-associated osteoporosis, remains a blind spot in nephrology with an immense treatment gap. Defining the bone phenotype is a prerequisite for the appropriate therapy of CKD-associated osteoporosis at the patient level. In the present review, we suggest 10 practical 'tips and tricks' for the assessment of bone health in patients with CKD. We describe the clinical, biochemical, and radiological evaluation of bone health, alongside the benefits and limitations of the available diagnostics. A bone biopsy, the gold standard for diagnosing renal bone disease, is invasive and not widely available; although useful in complex cases, we do not consider it an essential component of bone assessment in patients with CKD-associated osteoporosis. Furthermore, we advocate for the deployment of multidisciplinary expert teams at local, national, and potentially international level. Finally, we address the knowledge gaps in the diagnosis, particularly early detection, appropriate "real-time" monitoring of bone health in this highly vulnerable population, and emerging diagnostic tools, currently primarily used in research, that may be on the horizon of clinical practice.

Citing Articles

Association between psoas muscle mass index and bone mineral density in patients undergoing hemodialysis.

Ito K, Ookawara S, Sanayama H, Kakuda H, Kanai C, Iguchi K Sci Rep. 2025; 15(1):544.

PMID: 39748056 PMC: 11696570. DOI: 10.1038/s41598-024-84873-4.

References
1.
Evenepoel P, Cunningham J, Ferrari S, Haarhaus M, Javaid M, Lafage-Proust M . Diagnosis and management of osteoporosis in chronic kidney disease stages 4 to 5D: a call for a shift from nihilism to pragmatism. Osteoporos Int. 2021; 32(12):2397-2405. DOI: 10.1007/s00198-021-05975-7. View

2.
Evenepoel P, Cunningham J, Ferrari S, Haarhaus M, Javaid M, Lafage-Proust M . European Consensus Statement on the diagnosis and management of osteoporosis in chronic kidney disease stages G4-G5D. Nephrol Dial Transplant. 2020; 36(1):42-59. DOI: 10.1093/ndt/gfaa192. View

3.
Jorgensen H, Behets G, Viaene L, Bammens B, Claes K, Meijers B . Diagnostic Accuracy of Noninvasive Bone Turnover Markers in Renal Osteodystrophy. Am J Kidney Dis. 2021; 79(5):667-676.e1. DOI: 10.1053/j.ajkd.2021.07.027. View

4.
Vrist M, Ostergaard A, Langaa S, Mose F, Fynbo C, Theil J . Bone Turnover, Mineralization, and Volume Estimated by 18F-Sodium Fluoride PET/CT and Biomarkers in Chronic Kidney Disease: Mineral and Bone Disorder Compared with Bone Biopsy. Am J Nephrol. 2022; 53(6):490-502. DOI: 10.1159/000524961. View

5.
Aaltonen L, Koivuviita N, Seppanen M, Tong X, Kroger H, Loyttyniemi E . Correlation between F-Sodium Fluoride positron emission tomography and bone histomorphometry in dialysis patients. Bone. 2020; 134:115267. DOI: 10.1016/j.bone.2020.115267. View